8‐Oxoguanine Modified CircMTUS1 Drives PABPC1 Phase Separation to Promote Gastric Cancer Progression and Cisplatin Resistance via Autophagy
Source abstract
Abstract
ABSTRACT Gastric cancer (GC) is a major global health concern, as its prevention and treatment remain significant challenges. The 8‐oxoguanine (o8G) modification of circRNAs, alongside their capacity to orchestrate liquid‐liquid phase separation (LLPS) and autophagy, plays a pivotal role in driving tumor progression and determining therapeutic outcomes. Here, we identified the downregulation of circMTUS1 in GC and elucidated the upstream and downstream mechanisms governing its role in tumor progression and chemoresistance. We demonstrated that YBX1 induces o8G modification, which reduces circMTUS1 stability. Notably, circMTUS1 restoration markedly inhibits tumor growth both in vitro and in vivo. Mechanistically, circMTUS1 targeted PABPC1 through the LLPS to regulate stress granules (SG) formation and autophagy to inhibit GC progression and to affect the sensitivity to chemotherapy. Furthermore, the small‐molecule SG inhibitor ISRIB acts synergistically with circMTUS1 to significantly sensitize GC cells to cisplatin. Collectively, our data demonstrate that circMTUS1 suppresses GC progression through a pathway involving YBX1‐dependent o8G modification and PABPC1‐mediated regulation of SG and autophagy. Consequently, targeting circMTUS1 or its downstream SG may offer an effective strategy to enhance the chemosensitivity of gastric cancer.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Research and Splicing · Circular RNAs in diseases · RNA modifications and cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Gastroenterology First Affiliated Hospital of Nanjing Medical University Nanjing China
Department of Endocrinology Children's Hospital of Nanjing Medical University Nanjing China
Funding
National Natural Science Foundation of China
References (67)
Show source-provided references
1. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2. 10.1016/S0140‐6736(25)00052‐210.1016/S0140‐6736(25)00052‐2 ↗
3. 10.1016/S0140‐6736(20)31288‐510.1016/S0140‐6736(20)31288‐5 ↗
4. 10.1002/cac2.1253410.1002/cac2.12534 ↗
5. 10.1038/s41568‐024‐00721‐710.1038/s41568‐024‐00721‐7 ↗
6. 10.1146/annurev‐cellbio‐120420‐12511710.1146/annurev‐cellbio‐120420‐125117 ↗
7. 10.1186/s13045‐022‐01345‐w10.1186/s13045‐022‐01345‐w ↗
8. 10.1002/cac2.1238010.1002/cac2.12380 ↗
9. 10.1186/s12943‐023‐01887‐810.1186/s12943‐023‐01887‐8 ↗
10. 10.1016/j.drup.2024.10109710.1016/j.drup.2024.101097 ↗
11. 10.1016/j.prp.2023.15495010.1016/j.prp.2023.154950 ↗
12. 10.1016/j.ncrna.2025.08.00910.1016/j.ncrna.2025.08.009 ↗
13. 10.1161/CIRCRESAHA.124.32442110.1161/CIRCRESAHA.124.324421 ↗
14. 10.1186/s13046‐025‐03365‐z10.1186/s13046‐025‐03365‐z ↗
15. 10.1186/s12943‐025‐02283‐010.1186/s12943‐025‐02283‐0 ↗
16. 10.1038/s41556‐023‐01209‐610.1038/s41556‐023‐01209‐6 ↗
17. 10.1016/j.cell.2020.03.04610.1016/j.cell.2020.03.046 ↗
18. 10.1016/j.cell.2024.04.00210.1016/j.cell.2024.04.002 ↗
19. 10.1186/s12943‐025‐02239‐410.1186/s12943‐025‐02239‐4 ↗
20. 10.1038/s41586‐020‐2586‐010.1038/s41586‐020‐2586‐0 ↗
21. 10.1016/j.cell.2019.06.00510.1016/j.cell.2019.06.005 ↗
22. 10.1038/s12276‐022‐00822‐z10.1038/s12276‐022‐00822‐z ↗
23. 10.1186/s12943‐026‐02640‐710.1186/s12943‐026‐02640‐7 ↗
24. 10.1016/j.canlet.2023.21641110.1016/j.canlet.2023.216411 ↗
25. Helicobacter Pylori‐Enhanced hnRNPA2B1 Coordinates with PABPC1 to Promote Non‐m6A Translation and Gastric Cancer Progression10.1002/advs.202309712 ↗
26. 10.1016/j.canlet.2024.21671210.1016/j.canlet.2024.216712 ↗
27. DDX6 Undergoes Phase Separation to Modulate Metabolic Plasticity and Chemoresistance10.1038/s41467-025-66966-4 ↗
28. 10.1021/acsnano.3c0000110.1021/acsnano.3c00001 ↗
29. 10.1002/advs.20240326210.1002/advs.202403262 ↗
30. The Small Molecule ISRIB Reverses the Effects of eIF2α Phosphorylation on Translation and Stress Granule Assembly10.7554/eLife.05033 ↗
31. 10.1186/s12943‐020‐01270‐x10.1186/s12943‐020‐01270‐x ↗
32. 10.1080/15548627.2022.216442710.1080/15548627.2022.2164427 ↗
33. 10.1126/science.abf654810.1126/science.abf6548 ↗
34. 10.1016/j.molcel.2014.08.01910.1016/j.molcel.2014.08.019 ↗
35. 10.1186/s12943‐025‐02467‐810.1186/s12943‐025‐02467‐8 ↗
36. 10.1016/j.eclinm.2022.10140410.1016/j.eclinm.2022.101404 ↗
37. 10.1136/gutjnl‐2017‐31460010.1136/gutjnl‐2017‐314600 ↗
38. 10.2217/epi‐2019‐002910.2217/epi‐2019‐0029 ↗
39. 10.1016/j.phymed.2025.15728310.1016/j.phymed.2025.157283 ↗
40. 10.1186/s41021‐016‐0055‐710.1186/s41021‐016‐0055‐7 ↗
41. 10.1016/j.lungcan.2013.09.00910.1016/j.lungcan.2013.09.009 ↗
42. 10.1073/pnas.180691211510.1073/pnas.1806912115 ↗
43. 10.1042/BST2023025410.1042/BST20230254 ↗
44. FBL Promotes Cancer Cell Resistance to DNA Damage and BRCA1 Transcription via YBX1
45. 10.1038/s41419‐023‐05564‐y10.1038/s41419‐023‐05564‐y ↗
46. 10.1182/blood.202000967610.1182/blood.2020009676 ↗
47. 10.1002/ctm2.7027010.1002/ctm2.70270 ↗
48. 10.1158/0008‐5472.CAN‐24‐415410.1158/0008‐5472.CAN‐24‐4154 ↗
49. 10.1186/s13046‐024‐03103‐x10.1186/s13046‐024‐03103‐x ↗
50. 10.1021/acschembio.4c0083110.1021/acschembio.4c00831 ↗
51. 10.1038/s12276‐023‐01108‐810.1038/s12276‐023‐01108‐8 ↗
52. 10.1016/j.bbrc.2018.06.11210.1016/j.bbrc.2018.06.112 ↗
53. CircSHOC2 Regulates Steroid Hormone Synthesis in Ovarian Granulosa Cells Through the mir‐130b‐5p/ASH1L Pathway
54. 10.1186/s12943‐025‐02261‐610.1186/s12943‐025‐02261‐6 ↗
55. 10.1186/s12943‐025‐02447‐y10.1186/s12943‐025‐02447‐y ↗
56. CircRNA‐mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1/c‐Myc Axis10.1002/advs.202410591 ↗
57. 10.1016/j.canlet.2015.07.01010.1016/j.canlet.2015.07.010 ↗
58. 10.2217/fon‐2021‐010110.2217/fon‐2021‐0101 ↗
59. EIF4A3‐Mediated Biogenesis of circSTX6 Promotes Bladder Cancer Metastasis and Cisplatin Resistance10.1186/s13046-023-02932-6 ↗
60. 10.1038/s41568‐022‐00444‐710.1038/s41568‐022‐00444‐7 ↗
61. CircVAMP3 Drives CAPRIN1 Phase Separation and Inhibits Hepatocellular Carcinoma by Suppressing c‐Myc Translation10.1002/advs.202103817 ↗
62. Development of a Stress Response Therapy Targeting Aggressive Prostate Cancer10.1126/scitranslmed.aar2036 ↗
63. 10.1172/JCI13080910.1172/JCI130809 ↗
64. 10.1038/s41580‐023‐00585‐z10.1038/s41580‐023‐00585‐z ↗
65. 10.1038/s41392‐022‐01046‐310.1038/s41392‐022‐01046‐3 ↗
66. 10.1038/s41419‐024‐07057‐y10.1038/s41419‐024‐07057‐y ↗
67. 10.1038/s41467‐025‐63022‐z10.1038/s41467‐025‐63022‐z ↗